CL2014001397A1 - Pharmaceutical composition comprising a) gs-7977 and b) at least one pharmaceutically stable excipient; unit dosage form; composition preparation process; use of the composition to treat an infection caused by the hepatitis c virus. - Google Patents

Pharmaceutical composition comprising a) gs-7977 and b) at least one pharmaceutically stable excipient; unit dosage form; composition preparation process; use of the composition to treat an infection caused by the hepatitis c virus.

Info

Publication number
CL2014001397A1
CL2014001397A1 CL2014001397A CL2014001397A CL2014001397A1 CL 2014001397 A1 CL2014001397 A1 CL 2014001397A1 CL 2014001397 A CL2014001397 A CL 2014001397A CL 2014001397 A CL2014001397 A CL 2014001397A CL 2014001397 A1 CL2014001397 A1 CL 2014001397A1
Authority
CL
Chile
Prior art keywords
composition
hepatitis
virus
treat
dosage form
Prior art date
Application number
CL2014001397A
Other languages
Spanish (es)
Inventor
Reza Oliyai
Adrian S Ray
Darryl G Cleary
Charles J Reynolds
Miriam Michelle Berrey
Robert G Hindes
William T Symonds
Hongmei Mo
Christy M Hebner
Vahld Zia
Dimitrios Stefanidis
Rowchanak Pakdaman
Melissa Jean Casteel
Original Assignee
Gilead Pharmasset Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52002386&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014001397(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US13/661,509 external-priority patent/US20130109647A1/en
Application filed by Gilead Pharmasset Llc filed Critical Gilead Pharmasset Llc
Publication of CL2014001397A1 publication Critical patent/CL2014001397A1/en

Links

CL2014001397A 2011-11-29 2014-05-27 Pharmaceutical composition comprising a) gs-7977 and b) at least one pharmaceutically stable excipient; unit dosage form; composition preparation process; use of the composition to treat an infection caused by the hepatitis c virus. CL2014001397A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201113615645A 2011-11-29 2011-11-29
US201213055621A 2012-09-14 2012-09-14
US201261707459P 2012-09-28 2012-09-28
US13/661,509 US20130109647A1 (en) 2011-10-31 2012-10-26 Methods and compositions for treating hepatitis c virus

Publications (1)

Publication Number Publication Date
CL2014001397A1 true CL2014001397A1 (en) 2014-10-17

Family

ID=52002386

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014001397A CL2014001397A1 (en) 2011-11-29 2014-05-27 Pharmaceutical composition comprising a) gs-7977 and b) at least one pharmaceutically stable excipient; unit dosage form; composition preparation process; use of the composition to treat an infection caused by the hepatitis c virus.

Country Status (1)

Country Link
CL (1) CL2014001397A1 (en)

Similar Documents

Publication Publication Date Title
CL2014001016A1 (en) Condensed tricyclic compounds and their pharmaceutically acceptable salts; pharmaceutical composition that includes them; and its use in the treatment of a viral infection.
AR089578A1 (en) COMPOSITIONS, METHODS TO TREAT HEPATITIS C VIRUS AND PREPARATION PROCESS
CL2014001641A1 (en) Compounds derived from substituted nucleosides, nucleotides and analogs thereof; pharmaceutical composition; and use to improve or treat a viral infection.
UY33183A (en) INHIBITING COMPOUNDS OF VIRUS FLAVIVIRIDAE, PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT
CL2014001585A1 (en) Betulin derived compounds; pharmaceutical composition; and their use in the treatment and prevention of a hiv infection.
CL2014000370A1 (en) Tenofovir Alafenamide Hemifumarate; Preparation method; pharmaceutical composition that includes it; method to prepare the pharmaceutical composition; and use in the treatment of a hiv infection.
BR112014010545A2 (en) pharmaceutical composition, method for treating a patient infected with hepatitis c virus, use of a pharmaceutical composition
CL2013000727A1 (en) Compounds derived from imidazo [1,2-f] [1,2,4] triazinyl nucleosides; pharmaceutical composition that includes them; and its use for the treatment of a flaviviridae virus infection, particularly hepatitis c virus infections.
GT201400053A (en) VIRAL APPLICATION INHIBITORS
CL2012002489A1 (en) Compounds derived from silyl naphtho-imidazole; pharmaceutical composition; and its use to prevent or treat a hepatitis c virus infection.
GT201500021A (en) SULFAMOILARILAMIDAS AND ITS USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
CL2012000147A1 (en) Compounds derived from 5-ethynyl-3 (formylamino) thiophene-2-carboxylic acid, inhibitors of viruses of the flaviviridae family; pharmaceutical composition comprising a compound; and their use of the compounds in the preparation of drugs.
CL2013003229A1 (en) Hepatitis C virus (vhc) inhibitor compounds; pharmaceutical composition that includes them; and use in the treatment of a vhc infection.
BRPI1013394A2 (en) "compound, pharmaceutical composition, use of the compound, and method for treating a hepatitis c virus infected patient."
CL2015000870A1 (en) 2'-Chloro nucleoside analogs for HCV infection.
CL2012001959A1 (en) Compounds derived from thiophene-2-carboxylic acid, flaviviridae virus inhibitors; pharmaceutical composition that includes them; and its use for the treatment of a viral infection by flaviviridae.
CL2013001428A1 (en) Compound that inhibits hepatitis c virus (hcv) activity; pharmaceutical composition comprising the compound; hepatitis treatment method c.
CL2015000295A1 (en) Compounds derived from alkylpyrimidine; pharmaceutical composition that includes them; Use for the treatment of viral infections and other diseases.
EA026667B9 (en) Pharmaceutical composition for treating hepatitis c virus
CL2015001699A1 (en) Compounds derived from nucleosides, nucleotides and analogs thereof; pharmaceutical composition; and its use to prepare a useful medicine in the treatment of hepatitis c.
CL2014002093A1 (en) Piperidinopyrimidine derivative compounds; pharmaceutical composition that includes them; Use in the treatment of viral infections.
CL2014000245A1 (en) Compounds derived from nitrogen heterocycles, inhibitors of influenza virus replication; Preparation method; pharmaceutical composition; method to inhibit influenza virus replication in a biological sample or a patient.
CL2012003632A1 (en) Compounds derived from pyrazolo [1,5-a] pyrimidines or a pharmaceutically acceptable salt thereof; pharmaceutical composition that includes them; and its use to treat a pneumovirinae virus infection or a respiratory syncytial virus infection.
CL2014003012A1 (en) Capsule formulation comprising at least one compound of formula (i), solubilized; method of administration of the formulation; use to treat a hepatitis c virus infection.
BR112014005407A2 (en) compound, pharmaceutical composition, use of the compound or a pharmaceutically acceptable salt thereof, and method of treating an hcv infected patient